upsid organ growth boost ep guid
rais ep org growth
organ growth vs cse sale bil
estim consensu factset strength
pharma adv surgeri drove sale upsid
deliveri growth cc roughli in-lin although slightli lower
consensu potenti due greater fx headwind
ep cs estimate sale net cog roughli in-lin rel
estim lift lower non-op incom tax
partial off-set sg drive upsid ep
ep org growth guid rais ep guid
cse org growth guid rais cc
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc global manufactur provid
diversifi healthcar suppli equip area renal
hospit product
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
one-year valuat scenario base
ev/ebitda ebitda bil
scenario base high-growth segment grow
growth grow
one-year valuat grey scenario base
ev/ebitda grey ebitda bil
grey scenario base high-growth segment grow
growth grow
 close
sale
sale
estimate
ep
sale
sale
estimate
charl martineau univers toronto compani mention price
